# Bevacizumab in Recurrent Grade II and III Glioma

> **NCT01164189** · PHASE2 · COMPLETED · sponsor: **European Organisation for Research and Treatment of Cancer - EORTC** · enrollment: 155 (actual)

## Conditions studied

- Central Nervous System Tumors

## Interventions

- **BIOLOGICAL:** Bevacizumab
- **DRUG:** Temozolomide

## Key facts

- **NCT ID:** NCT01164189
- **Lead sponsor:** European Organisation for Research and Treatment of Cancer - EORTC
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-02
- **Primary completion:** 2017-01-19
- **Final completion:** 2017-09-24
- **Target enrollment:** 155 (ACTUAL)
- **Last updated:** 2019-02-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01164189

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01164189, "Bevacizumab in Recurrent Grade II and III Glioma". Retrieved via AI Analytics 2026-06-15 from https://api.ai-analytics.org/clinical/NCT01164189. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*